AUTHORS
Mathew J. Frank, MD, PhD, Neha Agarwal2, Hrishikesh Srinagesh, MD, MSCR3, Bita Sahaf, PhD4, Anne Marijn Kramer, MD, PhD5, Yi-Jiun Su, MD6, Kendall Kozy7, Priya Sharma8, LaTesha Jackson9, Annie Brown10, Kimi DeNoble11, Sharon Mavroukakis12, Claire Lohman13, Kristen Cunanan14, Josie Fabian15, Sushma Bharadwaj, MD16, Sally Arai, MD17, Laura Johnston, MD18, Robert Lowsky, MD19, Everett Meyer, MD, PhD20, Robert Negrin, MD21, Andrew Rezvani, MD22, Judith Anne Shizuru, MD, PhD23, Lekha Mikkilineni, MD, MA24, Hany Elmariah, MD,MS25, Parveen Shiraz, MD26, Surbhi Sidana, MD27, Wen-Kai Weng, MD, PhD28, Vanessa E Kennedy, MD29, Melody Smith, MD,MS30, Saurabh Dahiya, MD, FACP31, Lori Muffly, MD32, Crystal Mackall, MD33, Steven Feldman34, David Miklos, MD, PhD35
AFFILIATIONS
1 Stanford University, Stanford, United States
2 Stanford University, Stanford, United States
3 Stanford University, Stanford, United States
4 Stanford University, Stanford, United States
5 Stanford University, Stanford, United States
6 Stanford University, Stanford, United States
7 Stanford University, Stanford, United States
8 Stanford University, Stanford, United States
9 Stanford University, Stanford, United States
10 Stanford University, Stanford, United States
11 Stanford University, Stanford, United States
12 Stanford University, Stanford, United States
13 Stanford University, Stanford, United States
14 Stanford University, Stanford, United States
15 Stanford University, Stanford, United States
16 Stanford University, Stanford, United States
17 Stanford University, Stanford, United States
18 Stanford University, Stanford, United States
19 Stanford University, Stanford, United States
20 Stanford University, Stanford, United States
21 Stanford University, Stanford, United States
22 Stanford University, Stanford, United States
23 Stanford University, Stanford, United States
24 Stanford University, Stanford, United States
25 Stanford University, Stanford, United States
26 Stanford University, Stanford, United States
27 Stanford University, Stanford, United States
28 Stanford University, Stanford, United States
29 Stanford University, Stanford, United States
30 Stanford University, Stanford, United States
31 Stanford University, Stanford, United States
32 Stanford University, Stanford, United States
33 Stanford University, Stanford, United States
34 Stanford University, Stanford, United States
35 Stanford University, Stanford, United States
ABSTRACT
Introduction:
CD19-directed CAR T cell therapies (CAR19) have improved the outcomes of patients with non-Hodgkin Lymphoma (NHL); however, those who progress after CAR19 have poor outcomes. An autologous CD22-targeting CAR T-cell therapy (CAR22) demonstrated a 68% overall response rate (ORR) and 53% complete response rate (CRR) in a phase 1 clinical trial of 38 patients with Large B-cell lymphoma (LBCL) who progressed after CAR19. At the identified recommended phase 2 dose of 1 million CAR+ T-cells/kg, the median overall survival (OS) was 25.7 months with no occurrences of grade 3+ cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Based on these promising results, we evaluated this CAR22 at this dose for the treatment of Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Burkitt’s Lymphoma (BL), Lymphoplasmacytic Lymphoma (LPL), and LBCL. The primary objectives of this single-center Phase 1b trial (NCT06340737) are to determine the initial safety and manufacturing feasibility of CAR22 in patients with FL (cohort 1), MCL (cohort 2), and other NHL subtypes. Secondary objectives include ORR, CRR, progression-free survival, and OS. Exploratory objectives included rates of measurable residual disease (MRD) by Clono-Seq for MCL and the impact of tumor CD22 expression on response and relapse. Notably, this trial did not adopt an altered manufacturing method used for the CD22 CAR T cell therapy, firicabtagene autoleucel (firi-cel). A multicenter Phase 2 FIRCE-1 trial evaluated firi-cel in patients with CAR19-progressed LBCL, but was terminated, in part, due to high rates of fatal IEC-HS.
Methods:
Eligible patients had adequate organ function, documented CD22 tumor expression by flow cytometry or IHC, and had received 2 lines of prior therapy (except for BL and POD24 FL, in which only 1 line or prior therapy was required). Prior CAR19 was allowed if <=5% of circulating CD3+ cells expressed the CAR. CAR22 was manufactured as previously described (Frank et. al. Lancet 2024). Standard Flu/Cy lymphodepletion was given before CAR22 infusion.
Results:
Between April 2024 and July 2026, 30 patients with NHL have been treated (FL: n = 11, MCL: n = 11, other 8, MZL=2, BL=1, LPL=1, and LBCL=4). The overall median age was 65 (36-84) and 66(36-77), 72(57-84), and 64(38-84) for FL, MCL, and other NHL subtypes, respectively; overall, 19 (63%) patients were male (by FL:64%, MCL: 73%, other subtypes: 50%). Enrolled patients had high-risk features. Patients with FL were POD24 (n=6) or had prior CAR19 (n=3) and received a median of 3 (range 1-8) prior lines of therapy (LOT). Patients with MCL had either TP53 abnormalities or complex karyotype (n=7), or had prior CAR19 (n=10), and received a median of 5 (3-9) LOT. Patients with other NHL subtypes had received a median of 6 (3-15) prior LOT, and 5 received a prior CAR19 (BL=1, LBCL=4). With a median follow-up of 11.5 mo (range 1.7-27.2 mo), the best ORR and CRR were 26 of 30 (87%) and 22 of 30 (73%), respectively. The best ORR and CRR by subtype: FL 100%/100%, MCL 100%/73%, MZL 50%/50%, BL 0%/0%, LPL 100%/0%, and LBCL 50%/50%. MRD became undetectable in 10 of 11 MCL patients.
No grade (Gr) 3+ CRS, ICANS, or IEC-HS have been observed. The overall rate of CRS was 73% (n=22, Gr 1:23%, Gr 2:50%), of ICANS was 7% (n=2, Gr 1:7%), and of IEC-HS was 30% (n=9, Gr 1:13%, Gr 2: 17%). CRS, ICANS, and IEC-HS rates by FL, MCL, and other NHL subtypes are CRS: 73%, 73%, 75%; ICANS: 9%,9%, 0%; and IEC-HS: 18%, 45%, and 25%, respectively. Of the 30 treated patients, 4 did not respond (1 BL, 1 MZL, and 2 LBCL) and 8 additional patients have progressed after initially responding (3 FL and 5 MCL). At the time of progression, 4 patients (2 with FL and 2 with MCL) had a reduction or loss of tumor CD22 expression. The median PFS and OS for the entire cohort have not been reached (NR). The median PFS and OS by subtype are for FL: NR and NR; for MCL: 3.1 months (2.5-NR) and 11 months (2.3-NR); and for all other subtypes: 11.5 months (0.6 -NR) and NR, respectively.
Conclusion:
Our data show that manufacturing is feasible across multiple lymphoma subtypes and CAR22, when manufactured as described, induces a high ORR without grade 3+ CRS, ICANS, or IECHS in high-risk patients with FL, MCL, and other NHL subtypes.
DISCLOSURES
Mathew J. Frank, MD, PhD: No relevant conflicts of interest to declare.